High dose idarubicin-based regimen for diffuse large cell AIDS-related non-Hodgkin's lymphoma patients: A pilot study

Haematologica

Volumn 86, Issue 10, 2001, Pages 1051-1059

  Gastaldi, R ^a   Martino, P ^a   Gentile, G ^a   Cafolla, A ^a   Cordone, I ^a   Giannini, G ^a   Torromeo, C ^a   Palmisano, L ^a   Picardi, V ^a   Andreotti, M ^a   Avvisati, G ^a   Mandelli, F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

AIDS NHL; Idarubicin; Response; Survival; Toxicity

Indexed keywords

ACICLOVIR; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIDANOSINE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; METHOTREXATE; ONDANSETRON; PENTAMIDINE; VINCRISTINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LYMPHOCYTE COUNT; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OUTPATIENT CARE; PILOT STUDY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VIRUS LOAD;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IDARUBICIN; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 0034766755     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Advances in the epidemiology of HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms
2. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981-1986)
3. AIDS-associated non-Hodgkin's lymphoma in San Francisco
4. Acquired immunodeficiency syndromerelated lymphoma
5. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival
6. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS
7. Treatment of AIDS-related lymphomas
8. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial
9. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy
10. Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: A single-institute study of 96 patients
11. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Analysis of AIDS Clinical Trials Group Protocol 142: Low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor
12. Clinical and virologic effects of recombinant human granulocytemacrophage colony-stimulating factor in patients received chemotherapy for human immunodeficiency virus associated non-Hodgkin's lymphomas: Results of a randomized trial
13. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
14. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: A study by the non-Hodgkin's Lymphoma Co-operative Study Group
15. Idarubicin in patients with diffuse large cell lymphomas: A randomized trial comparing VACOP-B (A = doxorubicin) vs VICOP-B (I = idarubicin)
16. Idarubicina ad alte dosi in polichemioterapia (CIOD) e rhG-CSF nel trattamento dei linfomi non Hodgkin a prognosi sfavorevole
17. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project
18. Report of the committee on Hodgkin's disease staging classification
19. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS adolescents and adults
20. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project
21. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
22. 3′-azido 3′deoxythymidine + methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virus-related non-Hodgkin's lymphomas
23. Treatment of HIV-related non-Hodgkin's lymphoma adapted to prognostic factors
24. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection
25. Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated nonHodgkin's lymphoma: Identification of a subgroup with favorable clinical outcome
26. AIDS-related non-Hodgkin's lymphomas: Molecolar genetics, viral infection and cytokine deregulation
27. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy
28. The effects of antineoplastic chemotherapy on HIV disease
29. T-cell immunodeficiency following cytotoxic antineoplastic therapy: A review
30. Treatment of AIDS-related non-Hodgkin's lymphoma with chemotherapy (CNOP) and r-hu-G-CSF: Clinical outcome and effect on HIV-1 viral load
31. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
32. HIV-associated non-Hodgkin's lymphoma: Highly active antiretroviral therapy improves remission rate of chemotherapy
33. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine cohort, France, 1986-1997
34. Acquired immunodeficiency syndrome-related lymphoma: Clinical aspects
35. Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy
36. HIV-associated non-Hodgkin lymphoma: Incidence, presentation, and prognosis
37. Therapeutic strategies for aggressive lymphomas
38. Relapsed lymphoma